(Circulation. 2000;101:385.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Immunoglobulin Adsorption in Patients With Idiopathic Dilated Cardiomyopathy
From the German Heart Institute Berlin (J.M., M.D., H.B., K.B., S.S., R.H.); Max-Delbrück-Center (G.W., E.N.); and IMTOX, Immunbiologische Forschungs GmbH (R.K.), Berlin, Germany.
Correspondence to Johannes Müller, MD, German Heart Institute Berlin (Deutsches Herzzentrum Berlin), Augustenburger Platz 1, 13353 Berlin, Germany. E-mail jmueller{at}dhzb.de
Background—Idiopathic dilated cardiomyopathy (IDC) frequently is a progressive disease without causative therapy options. Following the hypothesis that in certain patients autoantibodies against cardiac structures may induce, maintain, or promote the progression of the disease, we investigated whether the elimination of these autoantibodies through immunoadsorption would improve cardiac function.
Methods and Results—This prospective case-control study included 34 patients with IDC. Each patient presented with moderate to severe heart failure and evidence of autoantibodies directed against ß1-adrenoceptors (ß1-AABs). Seventeen patients received standard medical therapy (control group), whereas 17 were also treated with immunoadsorption (treatment group) to eliminate ß1-AABs. A 1-year follow-up included echocardiographic assessment of left ventricular ejection fraction and internal diameters, ß1-AAB levels, and clinical status every 3 months. Within 1 year, the mean±SD left ventricular ejection fraction rose from 22.3±3.3% to 37.9±7.9% (P=0.0001) in the treatment group, with a relative increase of 69.9%. However, in the control group, no overall increase was seen (from 23.8±3.0% to 25.2±5.9%, P=0.3154). Left ventricular diameter in diastole decreased by 14.5% from 74.5±7.1 to 63.7±6.0 mm in the treatment group (P=0.0001) and by 3.8% (P=0.2342) in the control group. In the treatment group, the NYHA functional rating improved after immunoadsorption (P=0.0001). ß1-AABs did not increase anew.
Conclusions—In IDC, the use of immunoadsorption is superior to the use of standard medical therapy. It significantly improves cardiac performance and clinical status.
Key Words: dilated cardiomyopathy • autoantibodies
This article has been cited by other articles:
 |
|
 |
|
  D. C. Kem, X. Yu, E. Patterson, S. Huang, S. Stavrakis, B. Szabo, L. Olansky, J. McCauley, and M. W. Cunningham Autoimmune Hypertensive Syndrome Hypertension, November 1, 2007; 50(5): 829 - 834. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Amital, M. Heilweil-Harel, R. Ulmansky, M. Harlev, E. Toubi, A. Hershko, and Y. Naparstek Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption Rheumatology, September 1, 2007; 46(9): 1433 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gupta Heartache of Fc Receptors J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1693 - 1695. [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, P. Eichler, C. Trimpert, S. B. Felix, and A. Greinacher Fc{gamma} Receptors IIa on Cardiomyocytes and Their Potential Functional Relevance in Dilated Cardiomyopathy J. Am. Coll. Cardiol., April 24, 2007; 49(16): 1684 - 1692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Matsumoto, I.-K. Park, and K. Kohyama B-Cell Epitope Spreading Is a Critical Step for the Switch from C-Protein-Induced Myocarditis to Dilated Cardiomyopathy Am. J. Pathol., January 1, 2007; 170(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, L. Larsson, E. Haugen, O. Fedorkova, E. Angwald, F. Waagstein, and M. Fu Effects of autoantibodies removed by immunoadsorption from patients with dilated cardiomyopathy on neonatal rat cardiomyocytes Eur J Heart Fail, August 1, 2006; 8(5): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A L. Caforio, L Daliento, A Angelini, S Bottaro, A Vinci, G Dequal, F Tona, S Iliceto, G Thiene, and W J McKenna Autoimmune myocarditis and dilated cardiomyopathy: focus on cardiac autoantibodies Lupus, September 1, 2005; 14(9): 652 - 655. [Abstract] [PDF]
|
|
|
|
 |
|
 E. Adler and V. Fuster SCN5A--A Mechanistic Link Between Inherited Cardiomyopathies and a Predisposition to Arrhythmias? JAMA, January 26, 2005; 293(4): 491 - 493. [Full Text] [PDF]
|
|
|
|
 |
|
 C. del Corsso, A. C. C. de Carvalho, H. F. Martino, and W. A. Varanda Sera from patients with idiopathic dilated cardiomyopathy decrease ICa in cardiomyocytes isolated from rabbits Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1928 - H1936. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, Y. Staudt, M. Dorr, M. Bohm, F. Knebel, A. Hummel, L. Wunderle, M. Tiburcy, K. D. Wernecke, G. Baumann, et al. Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy J. Am. Coll. Cardiol., August 18, 2004; 44(4): 829 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W Mason Myocarditis and dilated cardiomyopathy: An inflammatory link Cardiovasc Res, October 15, 2003; 60(1): 5 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.B. Felix, A. Staudt, and G. Baumann Immunoadsorption as a new therapeutic principle for treatment of dilated cardiomyopathy Eur. Heart J. Suppl., December 1, 2002; 4(suppl_I): I63 - I68. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Wallukat, J. Muller, and R. Hetzer Specific Removal of {beta}1-Adrenergic Autoantibodies from Patients with Idiopathic Dilated Cardiomyopathy N. Engl. J. Med., November 28, 2002; 347(22): 1806 - 1806. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Staudt, M. Bohm, F. Knebel, Y. Grosse, C. Bischoff, A. Hummel, J. B. Dahm, A. Borges, N. Jochmann, K. D. Wernecke, et al. Potential Role of Autoantibodies Belonging to the Immunoglobulin G-3 Subclass in Cardiac Dysfunction Among Patients With Dilated Cardiomyopathy Circulation, November 5, 2002; 106(19): 2448 - 2453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hjalmarson, M. Fu, and R. Mobini Who are the enemies? Inflammation and autoimmune mechanisms Eur. Heart J. Suppl., November 1, 2002; 4(suppl_G): G27 - G32. [Abstract] [PDF]
|
|
|
|
|
|
A. Baba, T. Yoshikawa, and S. Ogawa Autoantibodies produced against sarcolemmal Na-K-ATPase: possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., September 18, 2002; 40(6): 1153 - 1159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Burch Heart failure in the young Heart, August 1, 2002; 88(2): 198 - 202. [Full Text] [PDF]
|
|
|
|
|
|
A. L.P. Caforio, N. J. Mahon, F. Tona, and W. J. McKenna Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance Eur J Heart Fail, August 1, 2002; 4(4): 411 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Felix, A. Staudt, M. Landsberger, Y. Grosse, V. Stangl, T. Spielhagen, G. Wallukat, K. D. Wernecke, G. Baumann, and K. Stangl Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption J. Am. Coll. Cardiol., February 20, 2002; 39(4): 646 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Engelhardt, Y. Grimmer, G.-H. Fan, and M. J. Lohse Constitutive Activity of the Human beta 1-Adrenergic Receptor in beta 1-Receptor Transgenic Mice Mol. Pharmacol., October 1, 2001; 60(4): 712 - 717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Liu and J. W. Mason Advances in the Understanding of Myocarditis Circulation, August 28, 2001; 104(9): 1076 - 1082. [Full Text] [PDF]
|
|
|
|
|
|
I. Schimke, J. Muller, F. Priem, I. Kruse, B. Schon, J. Stein, R. Kunze, G. Wallukat, and R. Hetzer Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption J. Am. Coll. Cardiol., July 1, 2001; 38(1): 178 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Mann Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: has the time come for randomized clinical trials? J. Am. Coll. Cardiol., July 1, 2001; 38(1): 184 - 186. [Full Text] [PDF]
|
|
|
|
|
|
A. Staudt, F. Schaper, V. Stangl, A. Plagemann, M. Bohm, K. Merkel, G. Wallukat, K. D. Wernecke, K. Stangl, G. Baumann, et al. Immunohistological Changes in Dilated Cardiomyopathy Induced by Immunoadsorption Therapy and Subsequent Immunoglobulin Substitution Circulation, June 5, 2001; 103(22): 2681 - 2686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Chiale, I. Ferrari, E. Mahler, M. A. Vallazza, M. V. Elizari, M. B. Rosenbaum, and M. J. Levin Differential Profile and Biochemical Effects of Antiautonomic Membrane Receptor Antibodies in Ventricular Arrhythmias and Sinus Node Dysfunction Circulation, April 3, 2001; 103(13): 1765 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iwata, T. Yoshikawa, A. Baba, T. Anzai, I. Nakamura, Y. Wainai, T. Takahashi, and S. Ogawa Autoimmunity Against the Second Extracellular Loop of {beta}1-Adrenergic Receptors Induces {beta}-Adrenergic Receptor Desensitization and Myocardial Hypertrophy In Vivo Circ. Res., March 30, 2001; 88(6): 578 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iwata, T. Yoshikawa, A. Baba, T. Anzai, H. Mitamura, and S. Ogawa Autoantibodies against the second extracellular loop of beta1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy J. Am. Coll. Cardiol., February 1, 2001; 37(2): 418 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gullestad, H. Aass, J. G. Fjeld, L. Wikeby, A. K. Andreassen, H. Ihlen, S. Simonsen, J. Kjekshus, S. Nitter-Hauge, T. Ueland, et al. Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure Circulation, January 16, 2001; 103(2): 220 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hetzer, J. H. Muller, Y.-G. Weng, M. Loebe, and G. Wallukat Midterm follow-up of patients who underwent removal of a left ventricular assist device after cardiac recovery from end-stage dilated cardiomyopathy J. Thorac. Cardiovasc. Surg., November 1, 2000; 120(5): 843 - 855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H Halfmann Immunoadsorption as a new treatment option for patients with idiopathic dilated cardiomyopathy Perfusion, July 1, 2000; 15(4): 333 - 336. [PDF]
|
|